Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | POLG | P54098 | 1/20 | 0.47 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15633311 | 1.00 | FGFR1 (0.52) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL15633883 | 0.91 | FGFR1 (0.58) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL15633299 | 0.91 | FGFR1 (0.58) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL15633324 | 0.88 | FGFR1 (0.52) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL15633312 | 0.88 | FGFR1 (0.52) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL21318454 | 0.80 | CYP3A4 (0.53) | FGFR1CYP3A4CYP2D6 | |
| SCHEMBL15633881 | 0.80 | CYP3A4 (0.51) | FGFR1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL15633919 | 0.80 | CYP3A4 (0.51) | FGFR1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL15633489 | 0.80 | CYP3A4 (0.51) | FGFR1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL15634070 | 0.80 | CYP3A4 (0.51) | FGFR1ALDH1A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550803-B2 | Method to improve antiviral activity of nucleotide analogue drugs | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140100186-A1 | METHOD TO IMPROVE ANTIVIRAL ACTIVITY OF NUCLEOTIDE ANALOGUE DRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100186-A1 | METHOD TO IMPROVE ANTIVIRAL ACTIVITY OF NUCLEOTIDE ANALOGUE DRUGS | PNP, TYMP, ADAR | FGFR1 3452/4885SLC22A6 1704/4885ABCB11 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.